Frontier Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Frontier Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-10,610	Closed	-$488K	–	348
2016 Q3	$488K	Sell	10,610 -1,576	-13%	-$82.2K	﹤0.01%	303
2016 Q2	$612K	Sell	12,186 -1,167	-9%	-$62.1K	0.01%	298
2016 Q1	$715K	Sell	13,353 -1,767	-12%	-$104K	0.01%	304
2015 Q4	$992K	Sell	15,120 -3,657	-19%	-$226K	0.01%	314
2015 Q3	$1.06M	Sell	18,777 -5,823	-24%	-$378K	0.01%	313
2015 Q2	$1.45M	Hold	24,600	–	–	0.01%	318
2015 Q1	$1.53M	Sell	24,600 -25,678	-51%	-$1.49M	0.01%	319
2014 Q4	$2.89M	Buy	50,278 +1,192	+2%	+$66.4K	0.02%	315
2014 Q3	$2.64M	Buy	49,086 +560	+1%	+$29.7K	0.02%	303
2014 Q2	$2.54M	Sell	48,526 -20,955	-30%	-$1.07M	0.02%	303
2014 Q1	$3.67M	Buy	69,481 +2,521	+4%	+$117K	0.03%	306
2013 Q4	$2.68M	Sell	66,960 -7,620	-10%	-$300K	0.02%	302
2013 Q3	$2.82M	Sell	74,580 -7,500	-9%	-$293K	0.02%	310
2013 Q2	$3.22M	Buy	+82,080	New	+$3.2M	0.03%	312

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Frontier Capital Management's TEVA Position: Q4 2016 in Review

Frontier Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 10,610 shares — an estimated $488K sold.

Frontier Capital Management first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $3.67M in Q1 2014. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Frontier Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Frontier Capital Management sold 10,610 Teva Pharmaceuticals shares in Q4 2016, an estimated $488K.
Frontier Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Frontier Capital Management's Teva Pharmaceuticals position peaked at $3.67M in Q1 2014.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Frontier Capital Management's 13F filing for Q4 2016, filed 3 Feb 2017.